Abstract
Background The increased transmission of SARS-CoV-2 variants of concern (VOC) which originated in the United Kingdom (B.1.1.7), South Africa (B1.351), Brazil (P.1) and in United States (B.1.427/429) requires a vigorous public health response, including real time strain surveillance on a global scale. Although genome sequencing is the gold standard for identifying these VOCs, it is time consuming and expensive. Here, we describe a simple, rapid and high-throughput reverse-transcriptase PCR (RT-PCR) melting temperature (Tm) screening assay that identifies these three major VOCs.
Methods RT-PCR primers and four sloppy molecular beacon (SMB) probes were designed to amplify and detect the SARS-CoV-2 N501Y (A23063T) and E484K (G23012A) mutations and their corresponding wild type sequences. After RT-PCR, the VOCs were identified by a characteristic Tm of each SMB. Assay optimization and testing was performed with RNA from SARS-CoV-2 USA WA1/2020 (WT), a B.1.17 and a B.1.351 variant strains. The assay was then validated using clinical samples.
Results The limit of detection (LOD) for both the WT and variants was 4 and 10 genomic copies/reaction for the 501 and 484 codon assays, respectively. The assay was 100% sensitive and 100% specific for identifying the N501Y and E484K mutations in cultured virus and in clinical samples as confirmed by Sanger sequencing.
Conclusion We have developed an RT-PCR melt screening test for the three major VOCs which can be used to rapidly screen large numbers of patient samples providing an early warning for the emergence of these variants and a simple way to track their spread.
Competing Interest Statement
D.A. receives research support and royalty payments from Cepheid, which sells the Xpert Xpress SARS-CoV-2 and Xpert Xpress SARS-CoV-2/Flu/RSV tests., S.C, is an employee of Cepheid and R.J. is a paid consultant for Cepheid.
Clinical Trial
Banked clinical specimens that were collected either for routine diagnostics or other research studies unrelated to the current manuscript were tested in this study.
Funding Statement
This study was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01 AI131617.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of de-identified clinical samples from confirmed COVID-19 positive and negative patients for PCR testing and sequencing was approved by the Rutgers Institutional Review Board under protocol numbers 20170001218 and 2020001541.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript was supplemented with an additional assay targeting E484K mutation. Methods, results and discussion are revised to include the new data. Added Table 1 detailing the primers and probes and the sequences from the text in the original manuscript was removed. Table 1 in the original manuscript is revised Table 2 in the revised manuscript. Fig. 1 is revised to include 484 data Fig. 2 is changed and includes peak height data for both assays Fig. 3. original Fig. 2 is now Fig. 3 and is revised to include 484 data. Fig. 4 is revised
Data Availability
The assay published here along with the primers and probes are made available freely for the readers
